Lei Lai Company's weight loss drug approved by the United States.

The Food and Drug Administration under its "National Priority Review Voucher" pilot program has approved Eli Lilly's Foundayo. Eli Lilly's stock price rose over 4%. The drug was approved 50 days after submission, ahead of its target date of January 20, 2027 for patient access through the Prescription User Fee Act. Foundayo was approved for the purpose of reducing excess body weight and for long-term weight management in obese adults or overweight adults with at least one weight-related comorbidity. The lowest self-pay dose starts at $149 per month. Eligible Medicare Part D beneficiaries will pay a monthly fee of $50, with availability starting as early as July 1. Foundayo will be offered through the LillyDirect platform, with shipments expected to begin on April 6, followed by widespread availability in US retail pharmacies and telehealth service channels shortly thereafter.